Certainly, hydroxychloroquine is in the peak news. Because Mr. President of USA commented in his official Twitter as well as press release also. Other countries also started following the same and looking for the medicine hydroxychloroquine. But let’s see what WHO recommending for this medicine,
“1WHO is actively following the ongoing clinical trials that are being conducted in response to COVID-19, including studies looking at the use of chloroquine and its derivative, hydroxychloroquine, for treatment and/or prevention. Currently, there is insufficient data to assess the efficacy of either of these medicines in treating patients with COVID-19, or in preventing them from contracting the coronavirus.
Chloroquine is currently recommended by WHO for the treatment of P. vivax malaria. In the context of the COVID-19 response, the dosage and treatment schedules for chloroquine and hydroxychloroquine that are currently under consideration do not reflect those used for treating patients with malaria. The ingestion of high doses of these medicines may be associated with adverse or seriously adverse health outcomes1.”
The Indian pharmaceutical industry has contributed immensely not just to Indian but to global healthcare outcomes. Indian pharmaceuticals industry is globally respected and is one of the most successful industries in India. It has contributed immensely to India’s healthcare outcomes and economy. World‐class capabilities and favorable market conditions over the last many years have ensured that India continues to be one of the most lucrative pharma markets in the world. India continues to play a material role in manufacturing various critical, high quality and low‐cost medicines for Indian and global markets.
